News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 31, 2014, 16:10 ET

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014. Cash and investments in...

Jul 22, 2014, 18:46 ET

Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2014 on Thursday, July 31, 2014,...

Jun 19, 2014, 15:29 ET

Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients

Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published...

Jun 12, 2014, 16:15 ET

US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK

 Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA)...

Jun 11, 2014, 07:05 ET

Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists

Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has...

Jun 01, 2014, 09:00 ET

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

 Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which...

May 31, 2014, 14:15 ET

Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting

Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in...

May 19, 2014, 08:00 ET

Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer

 Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel,...

May 16, 2014, 22:22 ET

Nektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City

 Nektar Therapeutics' (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton...

May 07, 2014, 16:15 ET

Nektar Therapeutics Reports Financial Results for the First Quarter of 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2014. Cash and investments in...

May 01, 2014, 16:10 ET

Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014,...

Apr 09, 2014, 09:00 ET

Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR

 Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer...

Feb 26, 2014, 16:15 ET

Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013. Cash and...

Feb 19, 2014, 16:15 ET

Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday,...

Jan 22, 2014, 21:59 ET

Nektar Therapeutics Prices Public Offering of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced the pricing of its previously announced underwritten public offering of 8,500,000...

Jan 21, 2014, 16:10 ET

Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock

Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") today announced that it has commenced an underwritten public offering of 8,500,000 shares of its...

Jan 18, 2014, 12:00 ET

Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium

Nektar Therapeutics' (Nasdaq: NKTR) presented favorable data today from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with...

Jan 14, 2014, 08:15 ET

Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

 Nektar Therapeutics (NASDAQ:NKTR) announced today that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for...

Jan 14, 2014, 08:00 ET

First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain

Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new...

Jan 08, 2014, 17:38 ET

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 32nd...